Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1060694 | 1.00 | POLB (0.50) | POLBTDP1SMN1; SMN2HTTNPC1 | |
| SCHEMBL16054838 | 0.91 | LMNA (0.44) | POLBTDP1SMN1; SMN2HTTNPC1 | |
| SCHEMBL10065266 | 0.91 | CYP2D6 (0.53) | POLBTDP1SMN1; SMN2HTTNPC1 | |
| SCHEMBL16054837 | 0.91 | LMNA (0.44) | POLBTDP1SMN1; SMN2HTTNPC1 | |
| SCHEMBL16054840 | 0.91 | LMNA (0.44) | POLBTDP1SMN1; SMN2HTTNPC1 | |
| SCHEMBL16054834 | 0.91 | LMNA (0.44) | POLBTDP1SMN1; SMN2HTTNPC1 | |
| SCHEMBL13078096 | 0.90 | SMN1; SMN2 (0.55) | POLBSMN1; SMN2HTTNPC1GAA | |
| SCHEMBL1080641 | 0.84 | POLB (0.38) | POLBTDP1SMN1; SMN2HTTNPC1 | |
| SCHEMBL1080643 | 0.84 | POLB (0.38) | POLBTDP1SMN1; SMN2HTTNPC1 | |
| SCHEMBL15462268 | 0.84 | POLB (0.38) | POLBTDP1SMN1; SMN2HTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2012-05-31 | — | — | US | claimed |
| EP-2451795-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | Ottawa Hospital Research Institute (CA) | 2012-05-16 | — | — | EP | claimed |
| WO-2011003191-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2011-01-13 | — | — | WO | claimed |
| EP-2451795-B1 | COMPOSITIONS AND USES FOR ENHANCING VIRUS PRODUCTION | OTTAWA HOSPITAL RES INST (CA) | 2016-07-13 | — | — | EP | disclosed |
| US-9283254-B2 | Compositions and methods for enhancing virus efficacy | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2016-03-15 | — | — | US | disclosed |
| US-20150202240-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-07-23 | — | — | US | disclosed |
| US-8940291-B2 | Compositions and methods for enhancing virus efficacy | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-01-27 | — | — | US | disclosed |
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2012-05-31 | — | — | US | disclosed |
| EP-2451795-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | Ottawa Hospital Research Institute (CA) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011003191-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | HAVCR2, MAVS, TSG101 | POLB 629/4885TDP1 1335/4885SMN1; SMN2 178/4885 |
| US-20150202240-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | HAVCR2, MAVS, TSG101 | POLB 629/4885TDP1 1335/4885SMN1; SMN2 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.